Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787

References

• HausheerFBainSPerryMComprehensive meta-analysis of survival outcomes from two randomized multicenter trials in first-line advanced non-small cell lung cancer in patients treated with the novel investigational antitumor-enhancing and chemoprotective agent TavoceptEuropean J Clin Med Oncol201021719
   Google Scholar
• American Cancer SocietyCancer Facts and Figures 2014American Cancer Society170Atlanta, GA
   Google Scholar
• Cancer, Feb 2014, Fact Sheet No 297 [webpage on the Internet]GenevaWorld Health Organization Available from: http://www.who.int/mediacenter/factsheets/fs297/en/index.htmlAccessed November 13, 2014
   Google Scholar
• RosellRRobinetGSzczesnaARandomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancerAnn Oncol200819236236917947225
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationAvastin LabelUS Food and Drug Administration2004 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125085s225lbl.pdfAccessed November 13, 2014
   Google Scholar
• HausheerFHKochatHParkerARNew approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agentCancer Chemother Pharmacol200352Suppl 1S3S1512819940
   PubMed Web of Science ®Google Scholar
• HausheerFHKanterPCaoSModulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agentsSemin Oncol19982555845999783598
   PubMed Web of Science ®Google Scholar
• BovenEVerschraagenMHulscherTMBNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenograftsEur J Cancer20023881148115612008205
   PubMed Web of Science ®Google Scholar
• TakedaKNegoroSMatsuiKPhase I safety and pharmacokinetic trial of BNP7787 in patients receiving cisplatin (CDDP) and paclitaxel (PTX) for advanced non-small cell lung cancer (NSCLC): an Osaka phase 1 study group trialAmerican Society of Clinical Oncology2002 Abstract 453
   Google Scholar
• PendyalaLSchwartzGSmithPZdanowiczJMurphyMHausheerFModulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapyCancer Chemother Pharmacol200351537638412682786
   PubMed Web of Science ®Google Scholar
• PalmerRHVernerssonEGrabbeCHallbergBAnaplastic lymphoma kinase: signalling in development and diseaseBiochem J2009420334536119459784
   PubMed Web of Science ®Google Scholar
• HornLPaoWEML4-ALK: honing in on a new target in non-small-cell lung cancerJ Clin Oncol200927264232423519667260
   PubMed Web of Science ®Google Scholar
• ZhangXZhangSYangXFusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expressionMol Cancer2010918820624322
   PubMed Web of Science ®Google Scholar
• GrandeEBolósMVArriolaETargeting oncogenic ALK: a promising strategy for cancer treatmentMol Cancer Ther20111056957921474455
   PubMed Web of Science ®Google Scholar
• ChiarleRVoenaCAmbrogioCPivaRInghiramiGThe anaplastic lymphoma kinase in the pathogenesis of cancerNat Rev Cancer200881112318097461
   PubMed Web of Science ®Google Scholar
• LeeCCJiaYLiNCrystal structure of the ALK (anaplastic lymphoma kinase) catalytic domainBiochem J2010430342543720632993
   PubMed Web of Science ®Google Scholar
• CuiJJTran-DubeMShenHStructure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)J Med Chem2011546342636321812414
   PubMed Web of Science ®Google Scholar
• MIFit Open Source Project [homepage on the Internet]2010 Available from: http://code.google.com/p/mifit/. Accessed
   Google Scholar
• MurshudovGNVaginAADodsonEJRefinement of macromolecular structures by the maximum-likelihood methodActa Crystallogr D Biol Crystallogr199753Pt 324025515299926
   PubMedGoogle Scholar
• LuXErringtonJChenVJCurtinNJBoddyAVNewellDRCellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell linesClin Cancer Res20006127127710656458
   PubMed Web of Science ®Google Scholar
• University of LeedsNature’s batteries’ may have helped power early lifeforms [webpage on the Internet]RockvilleScienceDaily5252010 Available from: http://www.sciencedaily.com/releases/2010/05/100525094906.htmAccessed June 1, 2012
   Google Scholar
• RappasMNiwaHZhangXMechanisms of ATPases - a multi-disciplinary approachCurr Protein Pept Sci2004528910515078220
   PubMed Web of Science ®Google Scholar
• VerschraagenMBovenEZegersIHausheerFHVan der VijghWJPharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case reportCancer Chemother Pharmacol200351652552912750838
   PubMed Web of Science ®Google Scholar
• BangYJThe potential for crizotinib in non-small cell lung cancer: a perspective reviewTher Adv Med Oncol20113627929122084642
   PubMedGoogle Scholar
• OuSHCrizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyondDrug Des Devel Ther20115471485
   PubMed Web of Science ®Google Scholar
• ShackletonMQuintanaEFearonERMorrisonSJHeterogeneity in cancer: cancer stem cells versus clonal evolutionCell2009138582282919737509
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• Dalle-DonneIRossiRColomboGGiustariniDMilzaniAProtein S-glutathionylation: a regulatory device from bacteria to humansTrends Biochem Sci2009342859619135374
   PubMed Web of Science ®Google Scholar
• MarinoSMGladyshevVNStructural analysis of cysteine S-nitrosylation: a modified acid-based motif and the emerging role of trans-nitrosylationJ Mol Biol2010395484485919854201
   PubMed Web of Science ®Google Scholar
• HouglandJLHicksKAHartmanHLKellyRAWattTJFierkeCAIdentification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivitiesJ Mol Biol2010395117619019878682
   PubMed Web of Science ®Google Scholar
• DietrichLEUngermannCOn the mechanism of protein palmitoylationEMBO Rep20045111053105715520806
   PubMed Web of Science ®Google Scholar
• ParkerARPetluruPNWuMZhaoMKochatHHausheerFHBNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitroMol Cancer Ther2010992558256720807779
   PubMed Web of Science ®Google Scholar